Strides Pharma Science Ltd announces it is selling a majority stake in its wholly owned subsidiary Pivot Path Pvt Ltd to a consortium led by Ascent Capital, with co-investor Vintage Classic. In a regulatory filing, the company says its board approved the strategic divestment at a meeting on June 27, 2026. The transaction includes an aggregate consideration of ₹100 crore for the sale of the majority stake and a primary infusion of ₹50 crore into Pivot Path by Ascent Capital to support the next phase of growth.
Strides will receive ₹75 crore at the initial closing of the deal and ₹25 crore on the first anniversary of closing, according to the filing. After completion, Pivot Path is reclassified from a wholly owned subsidiary to an associate company of Strides, with Strides holding a minority stake of 19.95%. The company frames the move as part of its strategic investment and capital allocation plan, following the completion of the proposed transaction.
